Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease
Details
Publication Year 2023-11,Volume 64,Issue #11,Page 1792-1800
Journal Title
Leukemia & Lymphoma
Publication Type
Research article
Abstract
Cytarabine-containing chemoimmunotherapy followed by autologous transplantation and rituximab maintenance achieves durable remissions for most patients with mantle cell lymphoma (MCL). However, patients with TP53-mutated disease have poor outcomes with standard approaches. We previously reported that allogeneic stem cell transplantation (alloSCT) achieved durable remissions in MCL, however follow-up among patients with TP53-mutated disease was limited. Here we report extended follow-up of the overall cohort (n = 36) and TP53-mutated subset (n = 13) (median follow-up 10.8 and 4.2 years, respectively). Estimated overall survival was 56% at 10 years for the overall cohort and 59% at 4 years for the TP53-mutated subset. Among patients with TP53-mutated disease, no relapses occurred beyond 6 months post-transplant. Survival after post-alloSCT disease relapse was poor (median 2.1 years). These data confirm that alloSCT can be curative in MCL, including patients with TP53-mutated disease, and should be considered for earlier utilization in this subgroup for whom conventional chemoimmunotherapy is ineffective.
Keywords
Adult; Humans; *Lymphoma, Mantle-Cell/therapy/drug therapy; Neoplasm Recurrence, Local; *Hematopoietic Stem Cell Transplantation/adverse effects; Rituximab/therapeutic use; Transplantation, Autologous; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Stem Cell Transplantation; Tumor Suppressor Protein p53/genetics; Neoplasia; clinical results; lymphoma and hodgkin disease; marrow and stem cell transpantation; molecular genetics
Department(s)
Clinical Haematology; Pathology
PubMed ID
37531077
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-12-20 06:44:10
Last Modified: 2023-12-20 06:44:39

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙